CHENNAI: Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in Indian pharma/biotech innova ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

Merck on Wednesday appeared to take a step towards addressing the looming Keytruda patent cliff. The company is closing in on ...

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody blockbuster Humira.

AbbVie’s offer is less than half the $160 billion that Pfizer offered for Allergan when it was peaking four years ago, a deal scuppered by a US crackdown on so-called ‘tax-inversion’ deals.

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

The stock's fall snapped a three-day winning streak.

Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data ...

Investors are digesting Trump's stiff tariffs on imports from more than a dozen countries and delayed the return of sweeping ...

Total aggregate value of the drugs generating the highest sales in 2024 rose 6.5% vs. 2023, and jumped 53% over five years.